Urinary Tract Infection Testing Market Size, Share, Opportunities, And Trends By Type (Urethritis, Cystitis, Pyelonephritis), By Indication (Complicated UTI, Uncomplicated UTI), By End-Use (General Practioner (GPs), Urologists, Urogynecologists, Urgent Care, Others), And By Geography - Forecasts From 2023 To 2028

The urinary tract infection testing market is anticipated to show steady growth during the forecast period.

Urinary tract infection (UTI) testing involves various methods to detect and diagnose infections affecting the urinary system like the kidneys, ureters, bladder, and urethra. The choice of testing method depends on the patient's symptoms, medical history, and the severity or recurrence of UTIs. The increasing prevalence of UTIs, growing awareness of UTIs along with the rise of an ageing population and chronic conditions has emerged as a significant driving force behind the substantial growth of the urinary tract infection testing industry.

Market Drivers:

• The increasing prevalence of UTIs bolsters the urinary tract infection testing market growth.

Urinary tract infection (UTI) tests are pivotal in diagnosing urinary tract infections, ensuring accurate identification of infections within the urinary system. Rapid diagnostic tests swiftly detect specific proteins or substances associated with UTIs, providing quick results for immediate treatment decisions. The surge in urinary tract infection cases globally has intensified the demand for efficient and accurate testing methods. As UTIs become more prevalent, people are aiming to seek timely medical attention and undergo UTI testing for early diagnosis and appropriate treatment. For instance, as per the NIH, urinary tract infections constitute a frequent cause for healthcare consultations. In the United States alone, UTIs lead to approximately 7 million office visits, 1 million emergency department visits, and more than 100,000 hospitalizations, accumulating an annual cost of $1.6 billion.

Growing awareness of UTIs drives urinary tract infection testing market growth.

Increased awareness among individuals about UTIs and their symptoms prompts proactive measures, including seeking diagnostic testing for early detection and treatment. This heightened awareness encourages individuals experiencing symptoms such as frequent urination, burning sensation during urination, or lower abdominal pain to promptly consult healthcare providers and undergo UTI testing, typically involving methods like urinalysis, urine cultures, or rapid diagnostic tests. The growing awareness of UTIs among individuals and healthcare professionals contributes to the expansion of the urinary tract infection testing market. As awareness leads to increased demand for UTI testing, there is a concurrent surge in the development and adoption of advanced testing technologies and methodologies.

• The ageing population drives the urinary tract infection testing market expansion.

The ageing population often faces an increased susceptibility to urinary tract infections (UTIs) due to various factors such as weakened immune systems, comorbidities, urinary incontinence, and the prevalence of catheter use among seniors. UTI testing in this demographic is crucial as symptoms in older adults might be subtle or atypical, leading to underdiagnosis and delayed treatment. For instance, according to a 2021 report by the World Trade Organization (WHO), By 2030, 1 in 6 people in the world will be aged 60 years or over. Additionally, between 2015 and 2050, the proportion of the world's population over 60 years will nearly double from 12% to 22%. Also, the number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

North America is expected to dominate the market.

North America is projected to account for a major share of the urinary tract infection testing market owing to the region’s increasing prevalence of Urinary tract infections (UTIs) and the growing affordability of UTI testing, particularly in countries like the United States and Canada. For instance, according to the National Institute of Health (NIH), Urinary tract infections (UTIs) are one of the most frequent clinical bacterial infections in women, accounting for nearly 25% of all infections and around 50–60% of women in the United States develop UTIs in their lifetimes, underscoring the rising prevalence of UTIs in the region and the critical need for accessible and accurate urinary tract infection (UTI) testing solutions in the region.

Market Challenges:

• Antibiotic overuse and resistance will restrain the urinary tract infection testing market growth.

The growth of the urinary tract infection testing industry may be restrained by the overuse of antibiotics for UTIs. Pervasive and indiscriminate use of antibiotics without proper diagnostic confirmation contributes significantly to the emergence of antibiotic-resistant bacteria creating an environment where bacteria evolve to become resistant to commonly prescribed antibiotics. As a result, the efficacy of UTI testing could be compromised due to the evolving nature of antibiotic resistance, leading to challenges in accurately diagnosing and effectively treating UTIs. These pose a challenge to the market's expansion and may require promotion of rational antibiotic use and education and awareness campaigns targeting both providers and the public are essential to emphasize the importance of proper UTI testing before antibiotic administration.

Market Developments

• June 2023: Sysmex Corporation introduced rapid antimicrobial susceptibility testing in Europe, designed for swift detection of bacteria and evaluation of antimicrobial efficacy using urine samples from patients with suspected UTIs. Employing distinctive proprietary microfluidic technology, this system provides AST results in just 30 minutes from the commencement of measurement.
• May 2022: Vela Diagnostics launched its new PathoKey® MP UTI ID and AMR PCR Test for research use. This multiplex PCR-based test enables the detection and differentiation of 14 pathogens responsible for urinary tract infections (UTI) and identifies 14 antimicrobial resistance (AMR) genes linked to resistance against 5 antibiotics, all within a single run.

Company Products

• Urinary Tract Infection (UTI) Testing Research Solutions: This real-time PCR solution by Thermofisher is optimized to provide results within 5 hours, surpassing traditional culture-based methods. Offering a seamless end-to-end process, it handles numerous samples daily with minimal intervention. The TaqMan OpenArray Urinary Tract Microbiota Comprehensive Plate efficiently identifies up to sixteen bacteria, swiftly pinpointing specific microorganisms causing urinary tract infections.
• Rapid Diagnostic Point of Care Test for UTI Detection: Ranox’s UTI testing aids in promptly identifying UTIs, enhancing precise and targeted treatment. It offers species-level identification and comprehensive patient profiling from a single urine sample. Detecting 23 bacterial strains, 1 fungal type, and 8 resistance markers, it delivers same-day results, aiding healthcare professionals in choosing the most suitable treatment for patients.
• Urinary tract infections test: Prisma SA's urinary tract infections test is designed for individuals seeking to detect the presence of leukocytes, blood, nitrites, or proteins in urine, suggesting a potential ongoing infection. This test utilizes plastic strips with various reactive sections. It is intended for both qualitative and semi-quantitative identification of leukocytes, blood, nitrites, and proteins in urine.

Segmentation

• By Type
  • Urethritis
  • Cystitis
  • Pyelonephritis
• By Indication
  • Complicated UTI
  • Uncomplicated UTI
• By End-Use
  • General Practioner (GPs)
  • Urologists
  • Urogynecologists
  • Urgent Care
  • Others
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Indonesia
    • Thailand

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Research Process 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Force Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. URINARY TRACT INFECTION TESTING MARKET BY TYPE

5.1. Introduction

5.2. Urethritis

5.3. Cystitis

5.4. Pyelonephritis

6. URINARY TRACT INFECTION TESTING MARKET BY INDICATION

6.1. Introduction

6.2. Complicated UTI

6.3. Uncomplicated UTI

7. URINARY TRACT INFECTION TESTING MARKET BY END-USER

7.1. Introduction

7.2. General Practioner (GPs)

7.3. Urologists

7.4. Urogynecologists

7.5. Urgent Care

7.6. Others

8. URINARY TRACT INFECTION TESTING MARKET, BY GEOGRAPHY

8.1. Introduction

8.2. North America

8.2.1. USA

8.2.2. Canada

8.2.3. Mexico

8.3. South America

8.3.1.  Brazil

8.3.2. Argentina

8.3.3. Others

8.4. Europe

8.4.1. Germany

8.4.2. UK

8.4.3. France

8.4.4. Spain

8.4.5. Others

8.5. Middle East and Africa

8.5.1. Saudi Arabia

8.5.2. UAE

8.5.3. Israel

8.5.4. Others

8.6. Asia Pacific

8.6.1. China

8.6.2. Japan

8.6.3. South Korea

8.6.4. India

8.6.5. Indonesia

8.6.6. Thailand

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

10. COMPANY PROFILES

10.1. Thermo Fisher Scientific

10.2. Beckman Coulter

10.3. Randox

10.4. Prima Lab SA

10.5. NxGen MDx

10.6. Acutis Diagnostics

10.7. Abingdon Simply Test

10.8. Mount Sinai

10.9. Cigna

Thermo Fisher Scientific

Beckman Coulter

Randox

Prima Lab SA

NxGen MDx

Acutis Diagnostics

Abingdon Simply Test

Mount Sinai

Cigna